Ergomed logo

ERGO - Ergomed Share Price

456p 2.0  0.4%

Last Trade - 8:35am

Sector
Healthcare
Size
Small Cap
Market Cap £218.3m
Enterprise Value £215.7m
Revenue £63.6m
Position in Universe 776th / 1834
Bullish
Bearish
Unlock ERGO Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ERGO Revenue Unlock ERGO Revenue

Net Income

ERGO Net Income Unlock ERGO Revenue

Normalised EPS

ERGO Normalised EPS Unlock ERGO Revenue

PE Ratio Range

ERGO PE Ratio Range Unlock ERGO Revenue

Dividend Yield Range

ERGO Dividend Yield Range Unlock ERGO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ERGO EPS Forecasts Unlock ERGO Revenue
Profile Summary

Ergomed plc is a provider of drug development services to the pharmaceutical industry. The Company operates through two segments: clinical research services (CRS), and drug safety and medical information services (DS&MI). It provides a range of clinical trial planning, management and monitoring services. It is focused on oncology, neurology and immunology, and the development of orphan drugs. It has two businesses: Services Business and Co-Development Business. The Services Business is a clinical research business providing services to the pharmaceutical and biotechnology industry. The Co-Development Business is a portfolio of partnerships with pharmaceutical and biotechnology companies, providing its drug development services in exchange for a carried interest in any revenues attributable to the drug asset, including out licensing milestones, as well as sales of the product. It provides clinical development, trial management and pharmacovigilance services to over 100 clients.

Directors
Last Annual December 31st, 2018
Last Interim June 30th, 2019
Incorporated September 29, 2000
Public Since July 15, 2014
No. of Shareholders: n/a
No. of Employees: 702
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Shares in Issue 48,082,177
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ERGO Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ERGO
Upcoming Events for ERGO
Wednesday 17th June, 2020 Estimate
Ergomed PLC Annual Shareholders Meeting
Similar to ERGO
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.